Carl Zeiss allies with Biological Detection, Inc.

17 Jun 2002

Carl Zeiss and Biological Detection, Inc., have announced a world-wide strategic alliance to develop and market both high precision and high throughout systems for cell-based drug discovery. New systems will employ optical and mechanical technologies for Zeiss and proprietary fluorescence detection and informatics tools from BDI, company spokesmen announced.Key to the alliance, Zeiss' American subsidy has made a substantial equity investment in BDI while Zeiss executive James A. Sharp has been elected to the BDI board of directors.